122 related articles for article (PubMed ID: 36331024)
21. [
Kim K; Kim H; Bae SH; Lee SY; Kim YH; Na J; Lee CH; Lee MS; Ko GB; Kim KY; Lee SH; Song IH; Cheon GJ; Kang KW; Kim SE; Chung JK; Kim EE; Paek SH; Lee JS; Lee BC; Youn H
Theranostics; 2020; 10(20):9315-9331. PubMed ID: 32802194
[TBL] [Abstract][Full Text] [Related]
22. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation.
Rangaraju S; Raza SA; Pennati A; Deng Q; Dammer EB; Duong D; Pennington MW; Tansey MG; Lah JJ; Betarbet R; Seyfried NT; Levey AI
J Neuroinflammation; 2017 Jun; 14(1):128. PubMed ID: 28651603
[TBL] [Abstract][Full Text] [Related]
23. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
[TBL] [Abstract][Full Text] [Related]
24. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
25. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeled R954 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography.
Kuo HT; Pan J; Lau J; Zhang C; Zeisler J; Colpo N; Bénard F; Lin KS
Mol Pharm; 2017 Mar; 14(3):821-829. PubMed ID: 28094956
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides.
Zhang C; Pan J; Lin KS; Dude I; Lau J; Zeisler J; Merkens H; Jenni S; Guérin B; Bénard F
Mol Pharm; 2016 Nov; 13(11):3657-3664. PubMed ID: 27669056
[TBL] [Abstract][Full Text] [Related]
31.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
32. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity.
Rashid MH; Kuyucak S
J Phys Chem B; 2014 Jan; 118(3):707-16. PubMed ID: 24397610
[TBL] [Abstract][Full Text] [Related]
33. Radiosynthesis and pre-clinical evaluation of [
Chopra S; Singh B; Koul A; Mishra AK; Robu S; Kaur A; Ghai A; Caplash N; Wester HJ
Appl Radiat Isot; 2019 Jul; 149():9-21. PubMed ID: 31003040
[TBL] [Abstract][Full Text] [Related]
34.
Ren J; Zhu S; Zhang G; Tan X; Qiu L; Lin J; Jiang L
Mol Pharm; 2022 Jul; 19(7):2620-2628. PubMed ID: 35674464
[TBL] [Abstract][Full Text] [Related]
35. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
36. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
37. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
40. PET Imaging of the P2X7 Ion Channel with a Novel Tracer [
Berdyyeva T; Xia C; Taylor N; He Y; Chen G; Huang C; Zhang W; Kolb H; Letavic M; Bhattacharya A; Szardenings AK
Mol Imaging Biol; 2019 Oct; 21(5):871-878. PubMed ID: 30632003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
